Safety profile of prasugrel and clopidogrel in patients with acute coronary syndromes in Switzerland
- Klingenberg, Roland
- Heg, Dik
- Räber, Lorenz
- Carballo, David
- Nanchen, David
- Gencer, Baris
- Auer, Reto
- Jaguszewski, Milosz
- Stähli, Barbara E
- Jakob, Philipp
- Templin, Christian
- Stefanini, Giulio G
- Meier, Bernhard
- Vogt, Pierre
- Roffi, Marco
- Maier, Willibald
- Landmesser, Ulf
- Rodondi, Nicolas
- Mach, François
- Windecker, Stephan
- Jüni, Peter
- Lüscher, Thomas F
- Matter, Christian M
DOIAbstract
OBJECTIVE To assess safety up to 1 year of follow-up associated with prasugrel and clopidogrel use in a prospective cohort of patients with acute coronary syndromes (ACS). METHODS Between 2009 and 2012, 2286 patients invasively managed for ACS were enrolled in the multicentre Swiss ACS Bleeding Cohort, among whom 2148 patients received either prasugrel or clopidogrel according to current guidelines. Patients with ST-elevation myocardial infarction (STEMI) preferentially received prasugrel, while those with non-STEMI, a history of stroke or transient ischaemic attack, age ≥75 years, or weight <60 kg received clopidogrel or reduced dose of prasugrel to comply with the prasugrel label. RESULTS After adjustment using propensity scores, the...
Add to ORKG